Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history:pooled analysis of ACLIFORM and AUGMENT

Autor:	D'Urzo, Anthony D., Singh, Dave, Donohue, James F., Kerwin, Edward M., Ribera, Anna, Molins, Eduard, Chuecos, Ferran, Jarreta, Diana, Gil, Esther Garcia
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine aclidinium Health Policy Public Health Environmental and Occupational Health COPD formoterol respiratory system circulatory and respiratory physiology respiratory tract diseases
Zdroj:	D'Urzo, A D, Singh, D, Donohue, J F, Kerwin, E M, Ribera, A, Molins, E, Chuecos, F, Jarreta, D & Gil, E G 2019, ' Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history : pooled analysis of ACLIFORM and AUGMENT ', International journal of chronic obstructive pulmonary disease, vol. 14, pp. 479-491 . https://doi.org/10.2147/COPD.S185502
DOI:	10.2147/COPD.S185502
Popis:	Background: Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups. Patients and methods: Data were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Patients (N=3,394) were analyzed by baseline airflow obstruction severity (moderate/severe), age (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______3818::9e9a1849d44c5b67002f49e0958b5c91 https://www.research.manchester.ac.uk/portal/en/publications/efficacy-of-aclidiniumformoterol-40012-g-analyzed-by-airflow-obstruction-severity-age-sex-and-exacerbation-history(3fb1251d-8079-4791-9b39-5a81426a0650).html Zobrazit plný text záznamu